The aging of subjects with hepatitis C virus and the impact of dual oral therapy for elder hepatitis C patients

Satoshi Oeda, Shinji Iwane, Keishiro Maeyama, Susumu Fujii, Naoko Furukawa, Takehiro Sadanaga, Ryoji Iwasaki, Yuichiro Eguchi, Keizo Anzai

Research output: Contribution to journalArticlepeer-review

Abstract

Saga University and Saga prefecture health promotion division assemble a hepatic disease database from 2012. Subjects with HCV in this database were analyzed. Two thousand four hundred and sixty subjects with HCV and 3110 subjects received reimbursement for HCV anti-viral treatment were analyzed. Subjects with HCV were born earlier than subjects received reimbursement (1944 ± 12 vs. 1952 ± 12, p < 0.001). Subjects received reimbursement had a lower rate of subjects born in -1939 than subjects with HCV (11.5% vs. 38.6%, p < 0.001). Subjects with dual oral therapy had a higher rate of patients born in -1939 than conventional interferon- based treatments (p<0.001). It is possible that dual oral therapy achieve more effective anti-viral treatment for elder HCV patients. We can predict that both untreated patients and post-treatment persons will be aging with the rise of treatment. The countermeasures to hepatitis on the aging are important.

Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalActa Hepatologica Japonica
Volume56
Issue number6
DOIs
Publication statusPublished - 2015 Jun 29
Externally publishedYes

Keywords

  • Aging
  • Chronic hepatitis C
  • Dual oral therapy
  • Elderly
  • Interferon

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'The aging of subjects with hepatitis C virus and the impact of dual oral therapy for elder hepatitis C patients'. Together they form a unique fingerprint.

Cite this